Medication Description: Filgrastim
Synonyms: Neupogen, Neupogen, Neupogen.
Polypeptide (non-glycolized) containing 175 amino acid residues. The molecular weight is 8800 daltons. (C 845 H 1330 N 223 O 243 S 9 ).
It is obtained by genetic engineering through Escherichia coli. Contains a human granulocyte colony-stimulating factor gene.
Stimulates granulocytopoiesis. Interacting with receptors on the surface of hematopoietic cells, accelerates the biosynthesis and release of neutrophils in the bone marrow.
Apply intravenously and subcutaneously.
Doses set individually depending on the evidence, the severity of the process and the sensitivity of the patient to the drug.
Treatment begins no earlier than 24 hours after the end of chemotherapy. With cytotoxic neutropenia, 500,000 U / kg per day is administered, with bone marrow transplantation, 1,000,000 U / kg per day, with severe chronic and congenital neutropenia, the initial dose is 1,200,000 U / kg per day. Treatment continues until normalization of neutrophils in the blood (usually about 2 weeks).
Side effects are rare. However, there may be pain in the bones and muscles, redness of the skin and pain at the injection site, allergic reactions.
Product form: injection solution in syringe tubes 0.5; 1 and 1.6 ml (30 000 000 and 48 000 000 IU) and in bottles of 1 ml (30 000 000 IU) and 1.6 ml (48 000 000 IU).
For infusion, the contents of the vial diluted in 5% glucose solution.